Leerink Partners Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7
Leerink Partners analyst Jeffrey La Rosa maintains Pyxis Oncology (NASDAQ: PYXS ) with a Outperform and lowers the price target from $9 to $7.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.